Background
Introduction
2006-2013 to assess occurrence of babesiosis among elderly Medicare beneficiaries ages 65 and above in coordination with CMS and within the SafeRx Project. The Analytical Files contain billing information on medical services rendered (e.g., diagnoses, procedures). The diagnoses and procedures are first recorded into medical records by healthcare providers (e.g., physicians), and then coded and submitted to Medicare for billing and reimbursement purposes, thus ending up in the CMS administrative databases. Specifically, the Inpatient, SNF, Outpatient, and Carrier SAFs contain claims data submitted by inpatient hospital providers, SNFs, institutional outpatient (e.g., hospital outpatient departments, rural health clinics), and noninstitutional providers (e.g., physicians, physician assistants, nurse practitioners), respectively. The Medicare Enrollment Files contain demographic and enrollment information and help to ascertain Medicare coverage eligibility. The Analytical and Enrollment Files were linked to ascertain babesiosis occurrence rates. The Medicare's Part D Prescription Drug Event File was used to extract dispensed prescription drug data in order to ascertain medication treatment of babesiosis. To be eligible for the study in a particular year, beneficiaries had to be enrolled in Medicare fee-for-service Parts A (i.e. hospital insurance) and B (i.e. physician insurance) for at least 365 consecutive days prior to and including the latest month of continuous enrollment in that year. Likely incident babesiosis cases were identified based on the first recording of the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code for babesiosis (088.82) during the calendar year, with no recorded babesiosis in the preceding 365 days.
The study assessed babesiosis occurrence rates by estimating the number of cases per 100,000 beneficiaries overall, by calendar year, gender, age, race, and state of residence. States with babesiosis rates of <2 per 100,000 were not displayed. The study also assessed 30-day allcause mortality as well as ascertained the recorded babesiosis diagnoses in different service settings (e.g., hospital inpatient, institutional outpatient, physician offices) and evaluated seasonal occurrence by diagnosis month for CYs 2006-2013. The seasonality assessment was based on the number of babesiosis cases in each month and the number of beneficiaries continuously enrolled in the fee-for-service Medicare (Parts A and B) within the 365 days of each month in the calendar year. The Medicare beneficiaries with babesiosis were assigned an age based on the diagnosis date, and those without babesiosis had age assessed at the beginning of the latest enrollment month in the year. Beneficiaries with babesiosis were excluded from the analyses of subsequent calendar years or diagnosis months. All statistical analyses, including Chi-Squared tests to compare babesiosis rates by gender and race as well as to ascertain babesiosis occurrence trends by calendar year and age, were conducted using SAS version 9.2.
Among the recorded babesiosis cases, our study investigated possible co-infections with two other tick-borne illnesses: Lyme disease and/or Ehrlichiosis. Lyme disease was identified by ICD-9-CM diagnosis code 088.81, whereas Ehrlichiosis was identified by one or more of the following diagnosis codes: 082.40, 082.41, and 082.49. A co-infection was defined as a case in which babesiosis and at least one of these additional diagnoses were recorded on the same claim (i.e. on the same doctor visit or hospital stay). Four mutually exclusive babesiosis groups were evaluated: babesiosis only; babesiosis and Lyme disease; babesiosis and Ehrlichiosis; and babesiosis, Lyme disease, and Ehrlichiosis. For each of these groups, the study investigated prescription drug use in the week (7 days) following the babesiosis diagnosis. As prescription drugs are covered under Medicare Part D, this analysis applied continuous Part D enrollment throughout the 7-day window. Prescription drugs were identified using National Drug Codes (NDC) and stratified into therapeutic categories. Prescription drug utilization was assessed as a percentage of continuously-enrolled cases with at least one NDC recorded.
Our study assessed the frequency of recorded diagnostic tests which can be utilized for detection of babesiosis infection [1, 3, 30] . Diagnostic tests were identified by Current Procedural Terminology codes recorded on the same claim as the babesiosis diagnosis and were categorized into four types: blood smear, tests to detect antibodies, tests to detect nucleic acids, and the other test (mononuclear cell antigen, quantitative [e.g., flow cytometry]). Utilization of specific diagnostic tests was ascertained as percentage of all babesiosis cases with at least one test recorded on the diagnosis claim, overall and by setting. Our investigation using large CMS databases was granted a categorical exemption by the FDA's IRB, as it uses only existing data and information is recorded in such a manner that subjects cannot be identified.
Results
A total of 10,305 elderly Medicare beneficiaries had a recorded babesiosis diagnosis during 2006-2013 study period, for an overall rate of about 5 per 100,000 persons. Table 1 shows overall and annual number of babesiosis cases with corresponding rates (per 100,000 elderly persons) for all beneficiaries as well as by age and sex. The results showed a significant increase in the national babesiosis occurrence during the eight-year period, overall and by sex, with the lowest number of babesiosis cases in 2007 (N = 852) and the largest number in 2013 (N = 1,848). Table 1 shows a significantly lower risk of babesiosis occurrence with increasing age (p<0.001). About 90% of babesiosis cases were elderly ages 65 to 84; and only 10% of cases were older elderly of 85 and above. The overall babesiosis rates (per 100,000) were significantly higher among males as compared to females, 5. The results show the summer months of June, July, and August to be the peak months for babesiosis occurrence. About half of all cases (52.1%) were diagnosed in the three summer months, whereas 75% of cases were diagnosed in the months of May through October. (Fig 1 ) Table 2 shows overall and annual number of babesiosis cases with corresponding rates (per 100,000 beneficiaries) by states. The highest overall babesiosis rates (per 100,000) were identified in Connecticut (46), Massachusetts (45), Rhode Island (42), New York (27) , and New Jersey (14) , with rates of up to 10 times higher than the U.S. national rate. The top five babesiosisendemic states accounted for 76.5% of all cases identified in the U.S. elderly. Other states also had babesiosis recorded, including but not limited to Maryland (7), Virginia (4), Pennsylvania (3), Florida (3), and California (2), which represented 14.5% of all cases recorded. Significantly increasing babesiosis occurrence trends were identified nationally and in most states displayed, with the highest rates occurring in 2013 overall and for many states, including but not limited to Massachusetts, Connecticut, Rhode Island, and New Jersey. Significantly increasing trends were also found in New Hampshire, Maine, Pennsylvania, Florida, California, and some other states. In contrast, significantly declining babesiosis occurrence trends were found in Maryland and Virginia, with the lowest rates in 2011 and 2013, respectively. (Table 2 ; the results are also shown in Figures A-R in S1 File)
Figures S-V in S1 File show diagnostic tests recorded in different settings for Medicare beneficiaries diagnosed with babesiosis. Blood smear test was recorded more frequently than other tests in the institutional settings, while antibody and nucleic acid tests were more commonly recorded in the physician office setting (Figures S-V in S1 File). Table 3 shows recorded (7) 65-74 5,754 (6) 536 (4) 439 (4) 676 (6) 832 (7) 731 (6) 755 (6) 716 (6) 1,069 (8) 75-84 3,513 (5) 355 (3) 315 (3) 423 (4) 511 (6) 446 (5) 475 (5) 382 (4) 606 (7) 85 1,038 (3) 103 (2) 98 (2) 123 (3) 153 (3) 131 (3) 136 (3) 121 (3) (4) 512 (3) 443 (3) 647 (4) 812 (6) 692 (5) 712 (5) 648 (4) 931 (6) 65-74 3,128 (6) 283 (4) 242 (4) 364 (6) 458 (7) 407 (6) 424 (7) 400 (6) 550 (8) 75-84 1,708 (4) 174 (3) 153 (3) 214 (4) 262 (5) 209 (4) 228 (4) 179 (4) 289 (6) 85 561 (2) 55 (2) 48 (2) 69 (2) 92 (3) 76 (2) 60 (2) 69 (2) (6) 482 (4) 409 (4) 575 (5) 684 (6) 616 (6) 654 (6) 571 (5) 917 (8) 65-74 2,626 (6) 253 (4) 197 (4) 312 (6) 374 (7) 324 (6) 331 (6) 316 (5) 519 (9) 75-84 1,805 (6) 181 (4) 162 (4) 209 (5) 249 (6) 237 (6) 247 (7) 203 (5) 317 (8) 85 477 (4) 48 (4) 50 (4) 54 (4) 61 (4) 55 (4) 76 (5) 52 (3) 81 (5) Age medication use within seven days of babesiosis diagnosis in the four mutually exclusive babesiosis groups. About 36% of babesiosis-only cases with any NDC recorded had a CDC-recommended [21] babesiosis treatment combination of atovaquone and azithromycin, and 38% had no recorded medication treatment, as listed in the table. In comparison, only 16% had the same babesiosis treatment combination and 42% had no recorded treatment among persons with both babesiosis and Lyme disease recorded on the same claims. About 32% of babesiosisonly cases had a recorded treatment with tetracyclines as compared to 49% of persons with both babesiosis and Ehrichiosis recorded. Of 10,305 cases, 32 (0.3%) had exchange transfusion within 7 days of diagnosis (data not shown).
Discussion
Our population-based study among the U.S. elderly showed a significant increase in the national babesiosis occurrence trends during the eight-year study period. The study identified the highest babesiosis occurrence in babesiosis-endemic states of Connecticut, Massachusetts, Rhode Island, New York, and New Jersey, with rates of up to 10 times higher than the U.S. national rates. A substantial number of recorded Babesia cases were also identified in Maryland, New Hampshire, Maine, Virginia, Pennsylvania, Florida, and California, thus suggesting an expansion of Babesia infection into non-endemic areas. In addition, significantly increasing babesiosis occurrence trends during the eight-year study period were identified in most states with babesiosis rates of 2 per 100,000, with the highest rates occurring in 2013 both nationally and in many endemic states. In contrast, most of the states with babesiosis rates of <2 per (14) 80 (9) 59 (7) 98 (11) 150 (17) 112 (13) 169 (19) 127 (14) 185 (21) Maryland c 312 (7) 43 (8) 34 (7) 60 (12) 44 (8) 39 (7) 24 (4) 28 (5) 40 (7) New Hampshire c 85 (7) 3 (2) 4 (3) 9 (6) 6 (4) 10 (7) 20 (13) 21 (13) 12 (7) Maine c 76 (6) 8 (4) 4 (2) 10 (6) 6 (4) 9 (5) 16 (10) 10 (6) 13 (8) District of Columbia 15 (4) 3 (7) 1 (2) 3 (7) 1 (2) 0 (0) 3 (7) 3 (7) 1 (2) Virginia c 245 (4) 25 (3) 30 (4) 58 (8) 33 (5) 28 (4) 26 (4) 23 (3) 22 (3) Minnesota c 104 (4) 6 (1) 8 (2) 8 (2) 18 (5) 17 (5) 28 (9) 5 (2) 14 (5)
Pennsylvania c 262 (3) 28 (2) 18 (2) 31 (3) 22 (2) 24 (3) 36 (4) 40 (4) 53 (5) Delaware 25 (3) 2 (2) 1 (1) 7 (7) 4 (4) 3 (3) 4 (4) 1 (1) 3 (3) Wisconsin c 111 (3) 5 (1) 13 (2) 14 (3) 10 (2) 17 (4) 23 (5) 8 (2) 21 (4) Florida c 393 (3) 29 (2) 33 (2) 44 (2) 70 (4) 50 (3) 53 (3) 59 (3) 55 (3) California c 279 (2) 15 (1) 10 (1) 41 (2) 49 (2) 31 (2) 43 (2) 40 (2) 50 (2) a Babesiosis rates are rounded to the nearest whole number. 100,000 did not have significant babesiosis occurrence trends during the study period (data not displayed), thus suggesting a possible lack of natural transmission. Babesiosis occurrence was significantly higher for males vs. females and for whites vs. non-whites, with the majority of babesiosis cases diagnosed in the months of May through October. The study suggests that blood smear is more commonly utilized for diagnosis in the institutional settings, whereas antibody and nucleic acid tests are more commonly used in the physician office setting. The results also suggest that about a quarter of cases are diagnosed based on antibody testing alone, which is a strategy that lacks the ability to discriminate between past exposure versus active infection, and needs further confirmation. The study results on medication treatment of babesiosis suggest a potentially frequent occurrence of inappropriate or lack of treatment, especially among babesiosis cases co-infected with either Ehrlichiosis and/or Lyme disease, which needs further investigation. Specifically, although the recommended treatment for babesiosis includes atovaquone plus azithromycin or clindamycin plus quinine [1] [2] [3] 20, 21] , the study identified only about 21% of cases with CDCrecommended babesiosis treatment combinations [21] , about 30% of cases with recorded potentially inappropriate tetracycline treatment, and a substantial proportion of cases (about 48%) with no recorded medication treatment. Persons co-infected with either Lyme disease (25) 809 (42) 239 (22) 40 (29) 61 (5) Atovaquone 1,037 (23) 758 (39) 212 (19) 35 (25) 32 (2) Clindamycin 87 (2) 57 (3) 17 (2) 2 (1) 11 (1) All Anti-Malarials 194 (4) 89 (5) 87 (8) 1 (1) 17 (1) Hydroxychloroquine Sulfate 86 (2) 22 (1) 50 (5) 1 (1) 13 (1) Quinine 37 (1) 29 (2) 7 (1) 0 (0) 1 (0)
All Cephalosporins 204 (5) 66 (3) 87 (8) 8 (6) 43 (3) Cefuroxime Axetil 96 (2) 27 (1) 40 (4) 6 (4) 23 (2) All Macrolides 1,241 (27) 830 (43) 290 (26) 42 (30) 79 (6) Azithromycin 1,156 (26) 808 (42) 248 (23) 40 (29) 60 (4) All Penicillins 248 (6) 85 (4) 75 (7) 10 (7) 78 (6) Amoxicillin 160 (4) 55 (3) 46 (4) 6 (4) 53 (4) All Tetracyclines 1,336 (30) 617 (32) 373 (34) 68 (49) 278 (21) Doxycycline Hyclate 1,229 (27) 571 (30) 323 (29) 64 (46) 271 (20) NDC Combinations Atovaquone + Azithromycin 929 (21) 700 (36) 170 (16) 32 (23) 27 (2) Clindamycin + Quinine 31 (1) 25 (1) 6 ( and/or Ehrlichiosis were less likely to have the recommended babesiosis treatment combinations and more likely to have no recorded medication treatment as compared to babesiosisonly group. Additionally, future population-based investigations of unconventional regimens are needed to help further ascertain current practice for treatment of babesiosis. Overall, our study findings, in concordance with CDC's national surveillance results, suggest increasing babesiosis occurrence trends over time, with the highest rate in 2013 [11, 38] . Although babesiosis has been a notifiable disease since January 2011, babesiosis occurrence as reported by states to CDC [10, 11, 38] was noticeably lower than the recorded babesiosis occurrence identified in our study, which could be due to under-reporting to CDC [10, 11] as well as a higher likelihood of under-diagnosing babesiosis in the general population versus elderly since babesiosis is more likely to be asymptomatic in younger individuals as compared to older persons [3, 5, 16, 17] . Similarly, in support of our study's results, surveillance in the babesiosisendemic states also suggests an increasing occurrence of babesiosis over time [39] [40] [41] [42] [43] [44] [45] . The findings of lower overall babesiosis occurrence in Wisconsin and Minnesota are supported by the literature and could be due to environmental factors as well as a potentially restricted occurrence of babesiosis to portions of those states [7, 27, 46] . As supported by the literature [3, 5, 9, [10] [11] [12] 39, 41, 47] , our study also shows that most of the babesiosis cases among the elderly are diagnosed in the months of May through October, with the peak occurrence in June, July, and August. These findings are likely related to increased activity of humans during summer months as well as the lifecycle and activity of the tick vector and mammalian hosts [1, [3] [4] [5] . In support of the published data [9] [10] [11] 13, [39] [40] [41] 47, 48] , our study further shows that babesiosis occurrence varies by gender and age, with higher rates among males as compared to females and in younger elderly as compared to older elderly persons. These findings could be associated with greater outdoor activity in males vs. females and in younger vs. older persons [49, 50] . Also, the study findings of substantially increased risk of human babesiosis infection in whites vs. non-whites could be due to a higher leisure-time physical activity in whites, which needs further investigation [49, 51, 52] . In support of the literature [18, 19, [53] [54] [55] , the study suggests a high co-infection rate with either Lyme disease or Ehrlichiosis for recorded babesiosis cases. Additionally, as most of the cases were diagnosed in the outpatient settings and resulted in a low 30-day mortality, our study, in concordance with the literature, suggests that a majority of babesiosis cases in the U.S. elderly are likely to be mild or moderate [2] [3] [4] [5] . In contrast, as supported by the literature [12, 13, 48] , our study identified a substantially higher mortality among babesiosis cases diagnosed in the inpatient setting.
Our study is based on the administrative databases, and consequently, limitations include: difficulty in identifying incident versus prevalent cases due to persistent parasitemia in some cases, possible misdiagnosis or misrecording of babesiosis, diagnostic tests, and medication use as well as lack of clinical detail for diagnosis code verification, identification of TTB cases, and ascertainment of specific Babesia species. The claims data also could not distinguish human granulocytic anaplasmosis caused by Anaplasma phagocytophilum (previously known as human granulocytic ehrlichiosis) from Ehrlichiosis infections. Since only about 50% of cases had at least one diagnostic test recorded, clinical investigations are needed to identify all diagnostic tests used and verify the validity of the recorded diagnostic testing in claims data. During the study period, there was no FDA-approved test for babesiosis screening in blood donors, although non-validated nucleic acid and antibody-based laboratory tests were available for diagnosis, which may have added a potential uncertainty and variability of the study results [4, 5, 23, 30] . Additionally, although Medicare administrative databases include information on laboratory tests performed, test results are not generally available in claims data. Future epidemiologic investigations will need medical record review to assess positive predictive value of the ICD-9-CM diagnosis code for babesiosis and further support its routine use in monitoring impact of the disease and public health interventions. The potential contribution of increased babesiosis awareness by medical community in non-endemic areas to the trends identified in our study merits further evaluation in appropriate settings. Also, beneficiary travels and shipments of blood components throughout the country may have contributed to the babesiosis occurrence trends identified in non-endemic states. The administrative data utilized do not provide population-based information on babesiosis occurrence among persons under 65 in the United States. However, as suggested by the literature, younger persons are more likely to be asymptomatic and, therefore, less likely to be diagnosed with the disease [3, 5, 16, 17] .
Our study is the largest-to-date national population-based investigation of babesiosis occurrence among the U.S. elderly, which shows variations in babesiosis occurrence by year, state of residence, age, gender, race, clinical setting, and diagnosis months. Overall, our eight-year study (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) identified increasing babesiosis occurrence trends over time, with highest rates in the five babesiosis-endemic states of Connecticut, Massachusetts, Rhode Island, New York, and New Jersey. The study, therefore, suggests the need for prevention strategies, including but not limited to deer population control, enhanced public awareness of tick-transmitted infections, and blood donor testing as well as the need for monitoring for potential expansion of human babesiosis to non-endemic areas. Human encroachment into tick and deer habitat, changes in climate, growth of the deer population, climatic effects on tick populations, and travel to babesiosis-endemic areas may be responsible for the spread of the infection to previously non-endemic states (e.g., Maine, New Hampshire, Pennsylvania) [3] [4] [5] [56] [57] [58] . Moreover, our study suggests the need for greater physician awareness of CDC-recommended babesiosis treatment [21] . As the results are likely to be indicative of babesiosis transmission rates in different geographic areas, our study will assist in determining appropriate blood donor testing strategies (e.g., universal donor testing, regional donor testing) for maximizing prevention of transfusion-transmission and minimizing negative effects on the U.S. blood supply. Since the elderly utilize most of the transfused blood [31] [32] [33] [34] , future studies are also needed to focus on evaluating the risk of TTB among the elderly. Overall, the results of this study suggest that large administrative databases could play an important role in assessing the occurrence (especially trends) of emerging infections in the United States and abroad as well as in helping to inform policies and evaluate the effectiveness of different risk reduction strategies to the nation's blood supply. 
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